{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:48:52Z","timestamp":1785163732371,"version":"3.55.0"},"reference-count":51,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2022,3,27]],"date-time":"2022-03-27T00:00:00Z","timestamp":1648339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The response with intravenous chemotherapy using cisplatin and paclitaxel in patients with advanced ovarian cancer is often substantial. However, this regression of the malignancy is not durable, and a majority of patients succumb to this disease process. It is possible that alternative types of chemotherapy and alternative routes of chemotherapy administration can improve the results of treatment and perhaps, reduce the morbidity and mortality that patients experience.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Regional chemotherapy treatments previously presented in the ovarian cancer literature were reviewed and critically analyzed. New methods for chemotherapy delivery for both advanced primary and recurrent ovarian cancer were reviewed. This included hyperthermic intraperitoneal chemotherapy (HIPEC), early postoperative intraperitoneal chemotherapy (EPIC), and normothermic intraperitoneal chemotherapy (NIPEC) long\u2010term.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>An important addition to perioperative chemotherapy delivery is the simultaneous use of heat with intraperitoneal drug delivery after a complete cytoreductive surgery. Drugs to be considered for HIPEC are cisplatin, gemcitabine, and melphalan. For EPIC, chemotherapy agents to consider include paclitaxel, pemetrexed, gemcitabine, and liposomal doxorubicin. For NIPEC, paclitaxel is the drug of choice usually combined with a systemic agent as bidirectional chemotherapy. Also, pemetrexed, gemcitabine, and liposomal doxorubicin are drugs to be considered for NIPEC in phase I\/II trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Innovative regimens of regional chemotherapy may improve the outcome of patients with advanced ovarian cancer. These chemotherapy treatments must be integrated with complete cytoreductive surgery and the availability of peritoneal access for repeated delivery of chemotherapy solutions.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jog.15224","type":"journal-article","created":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T03:42:58Z","timestamp":1648438978000},"page":"1306-1317","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimizing regional chemotherapy for epithelial ovarian cancer"],"prefix":"10.1111","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2431-7366","authenticated-orcid":false,"given":"Paul H.","family":"Sugarbaker","sequence":"first","affiliation":[{"name":"Washington Cancer Institute, Program in Peritoneal Surface Malignancy  Washington District of Columbia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,27]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612263352603"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1001"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052985"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01568"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104390"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.11.013"},{"key":"e_1_2_6_8_1","first-page":"17","volume-title":"Cytoreductive Surgery & Perioperative Chemotherapy for peritoneal surface malignancy. Textbook and video atlas","author":"Sugarbaker PH","year":"2017"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.ejgo4204096"},{"key":"e_1_2_6_10_1","first-page":"47","volume-title":"Cytoreductive Surgery & Perioperative Chemotherapy for peritoneal surface malignancy. Textbook and video atlas","author":"Van der Speeten K","year":"2017"},{"key":"e_1_2_6_11_1","first-page":"858","article-title":"Technical considerations in the use of intraperitoneal chemotherapy administered by a Tenckhoff catheter","volume":"154","author":"Jenkins J","year":"1982","journal-title":"Surg Gynecol Obstet"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1247-5_21"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02602252"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10048-4"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2002.1397"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-0443(94)71476-7"},{"key":"e_1_2_6_17_1","article-title":"Patterns of recurrence in women with ovarian cancer having hysterectomy for treatment of primary disease","author":"Sugarbaker PH","year":"2022","journal-title":"Chinese J Clin Oncol"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1247-5_26"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0959-8049(96)00178-5"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1055-3207(03)00038-3"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1188\/05.ONF.44-48"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2012.07.013"},{"key":"e_1_2_6_23_1","unstructured":"SugarbakerPH van derSpeetenK(Editors).J Gastrointestinal Oncol Focused Issue. Intraperitoneal chemotherapy for peritoneal metastases. HIPEC EPIC NIPEC PIPAC and more. Vol 12 Supplement 1 (April 2021)https.\/\/jgo.amegroups.com\/issue\/view\/531"},{"key":"e_1_2_6_24_1","first-page":"5790","article-title":"Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacologic studies","volume":"50","author":"Sugarbaker PH","year":"1990","journal-title":"Cancer Res"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2013.09.030"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.10-2-112"},{"key":"e_1_2_6_27_1","first-page":"185092","article-title":"Pharmacokinetic study of perioperative intravenous ifosfamide","volume":"2011","author":"Van der Speeten K","year":"2011","journal-title":"Int J Surg Oncol"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1055-3207(03)00031-0"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-009-0667-4"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.150"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708618"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.13940"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2020-02"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/827534"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-4157-9"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-003-0680-2"},{"key":"e_1_2_6_37_1","first-page":"871","article-title":"Determinants of paclitaxel penetration and accumulation in human solid tumor","volume":"290","author":"Kuh HJ","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-021-10193-w"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2020-06"},{"issue":"4","key":"e_1_2_6_40_1","first-page":"255","article-title":"Clinical value of anti\u2010adhesion agents used in laparotomy in obstetrics and gynecology","volume":"47","author":"Liu MM","year":"2012","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"e_1_2_6_41_1","unstructured":"SugarbakerPH.Intraperitoneal paclitaxel: Pharmacology clinical results and future prospects. J Gastrointestinal Oncol Focused Issue: Intraperitoneal chemotherapy for peritoneal metastases: HIPEC EPIC NIPEC PIPAC and more.2020. doi:https:\/\/doi.org\/10.21037\/jgo-2020-3"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2008.06.049"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.2963"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.12.013"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2000.0983"},{"issue":"1","key":"e_1_2_6_46_1","first-page":"51","article-title":"Gemcitabine in the treatment of ovarian cancer","volume":"10","author":"Hansen SW","year":"1999","journal-title":"Gynecol Oncol"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(03)00399-8"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0486"},{"issue":"11","key":"e_1_2_6_49_1","first-page":"11","article-title":"Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology","volume":"11","author":"Martin FJ","year":"1997","journal-title":"Oncology"},{"issue":"11","key":"e_1_2_6_50_1","first-page":"38","article-title":"Pegylated liposomal doxorubicin: antitumor activity in epithelial ovarian cancer or cancers of peritoneal origin","volume":"11","author":"Muggia FM","year":"1997","journal-title":"Oncology"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.03.035"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2018.11.065"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.15224","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jog.15224","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.15224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T19:53:30Z","timestamp":1692820410000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/jog.15224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,27]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.1111\/jog.15224"],"URL":"https:\/\/doi.org\/10.1111\/jog.15224","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"value":"1341-8076","type":"print"},{"value":"1447-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,27]]},"assertion":[{"value":"2021-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}